Biocon

“Biocon has always been R&D-led, fostering a culture of ideation, experimentation, and collaboration, keeping patients at the core of its business, which has led it to be placed among the ‘Top 10 Global Employers’ several years in a row by Science Magazine.” Kiran Mazumdar - Shaw, Executive Chairperson, Biocon Ltd. & Biocon Biologics  #BioconTop10 #SCTopEmployers

Recognizing the symptoms of #Diabetes early is crucial for better health outcomes. If you notice any of these signs, it’s important to take action: 💧 Increased thirst 😴 Fatigue 👀 Blurred vision 🚻 Frequent urination ⚖ Unexplained weight loss If you're experiencing any of these symptoms, it’s time to talk to your doctor. Early detection and management can help prevent complications. Let’s raise awareness together—start the conversation in your circle today! #TalkDiabetesInYourCircle

At #Biocon, innovation is at the heart of what we do. Recognized as an ‘Innovative Leader in the Industry,’ we foster a #culture of ideation, experimentation, and collaboration that keeps us ranked among the Top 10 Global Employers by Science Magazine. #BioconTop10 #SCTopEmployers 

#Biocon recently announced its earnings for the quarter ending September 30. In an interview with BusinessLine, Biocon CEO & Managing Director Siddharth Mittal outlined the company’s strategic direction and growth expectations. Despite this being a challenging quarter, Mittal said the company is poised for significant growth in the second half of FY25, driven by strategic product launches and increased volumes. He talked about upcoming launches, including Liraglutide API in the UK, Micafungin, and Daptomycin, increased capacity for synthetic and fermentation products, and cost-improvement initiatives such as addressing competitive pricing pressures and enhancing production capabilities. Reducing debt is a top priority for Biocon. Mittal shared that the company has successfully repaid $250 million of acquisition-related debt and is actively working to lower its net debt to EBITDA ratio from approximately 4.5-5 to a target range of 3-3.5. These efforts align with Biocon’s growth strategy and set guidelines for the year, positioning the company for a robust recovery and accelerated growth. For more details on Siddharth Mittal's insights and Biocon's future plans, read the full interview here. https://lnkd.in/eKBEJrSY

Time is Ticking⏰ Admissions for the Biocon KGI Certificate Program in Biosciences - Batch 28 are closing soon! Don’t miss this chance to make a real impact in the biotech world. Seize your spot today! To apply, click https://bit.ly/4gcBjM0 For more information, click https://bit.ly/3Zu1Ez8 #admissions #biology #biosciences #biotechnology #biochemistry #careers #engineers #freshers #lifesciences #microbiology #opportunities #pharma #technology

Are you talking about Diabetes in your circle? Around 540 million people across the globe have diabetes. The world needs to put brakes on the disease RIGHT NOW, and you can be in the driver’s seat. It’s #WorldDiabetesDay on November 14, and this entire month, we will talk about all you need to know about the condition. How about extending the Diabetes Awareness initiative by talking about #Diabetes in your circle? Let’s empower each other to make a difference. #Talk DiabetesInYourCircle

Thank you, Bioconites! Thank you to all our employees for making #Biocon an organization that consistently leads in both innovation and corporate social responsibility. Biocon ranked No. 9 on Science Magazine's 2024 Top Global Employers list! We remain committed to delivering solutions that improve global #healthcare. list! Read more: https://bit.ly/PR20241028 #BioconTop10 #SCTopEmployers #biotech #pharma #biopharma

Today, we celebrate the rich traditions, vibrant culture, and proud #heritage of Karnataka! From misty hills and serene coastlines to bustling cities and innovation hubs, #Karnataka is a land of unparalleled beauty, unity, and progress. As we honor this remarkable state, let’s embrace the spirit of Karnataka and the contributions of its people that make it truly extraordinary. #HappyKannadaRajyotsava

May the festival of #Diwali fill your life with light, joy, and prosperity. From all of us at Biocon, we wish you a bright and beautiful Diwali filled with happiness and togetherness. #HappyDiwali #FestivalOfLights

“Biocon Group’s overall #Q2FY25 financial and operational performance provides a foundation for improved performance as we move into the second half of the fiscal. Reported Operating Revenues of Rs 3,590 Cr reflect YoY growth of 8% on a like for like basis and core EBITDA and EBITDA margins of 28% and 20% respectively remain healthy. We had a robust performance in the Biosimilars business, up 19% on a like for like revenue basis, driven by strong market share gains in our US Oncology and Insulins franchises. Syngene has returned to sequential growth and has good visibility of a pickup in momentum in the coming quarters led by its Discovery Services and Biomanufacturing CMO business. Generics has continued to face price and demand pressures that have suppressed performance, but key new formulation launches in Q3 and Q4 provide the basis of a turnaround before the year end. All three businesses are tracking towards a better performance in the second half of the year, on the back of product approvals and unfolding market opportunities. “Biocon Biologics’ successful refinancing of its long-term debt of US$ 1.1 billion through a combination an $800 million USD bond listed on the Singapore Stock Exchange and a new $300 million syndicated loan facility was a credible success. This was Biocon Group’s debut bond issue and to be 3x oversubscribed speaks to strong investor confidence in our Biosimilars growth potential.” Kiran Mazumdar Shaw, Chairperson, Biocon Group. said on #Q2FY25 results. Read more: https://bit.ly/PRP20241030